Literature DB >> 8215739

A review of the clinical effectiveness of exercise therapy for intermittent claudication.

E Ernst1, V Fialka.   

Abstract

BACKGROUND: Intermittent claudication is both frequent and disabling. Conservative treatment consists of the elimination of risk factors, particularly smoking, drug treatment, and physical exercises. This review represents an attempt to define how effectively exercise prolongs the walking ability of claudicants.
METHODS: A computerized literature search was done to identify all controlled trials on the subject. In addition, other studies were admitted if they were in accordance with certain quality criteria.
RESULTS: Without exception, these studies showed that exercise can prolong the pain-free walking distance of claudicants. Even though this message seems uniform and convincing, one should point out that all trials are burdened with methodological flaws. The variability of increase in walking ability demonstrated in these studies is impressive and cannot be fully explained. A multitude of possible mechanisms could be involved in bringing about the clinical effect; at present it is impossible to define their relative importance.
CONCLUSIONS: The optimal exercise program should be supervised, performed regularly for at least 2 months, and of high intensity. Appropriate steps to guarantee patients' compliance must be taken. Even though many fundamental questions remain unanswered, it is justified to prescribe exercise therapy for intermittent claudication more generally than is realized in today's practice.

Entities:  

Mesh:

Year:  1993        PMID: 8215739

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

1.  Supervised exercise for intermittent claudication - an under-utilised tool.

Authors:  Joseph Shalhoub; Maher Hamish; Alun H Davies
Journal:  Ann R Coll Surg Engl       Date:  2009-06-25       Impact factor: 1.891

Review 2.  Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

3.  Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease.

Authors:  M M McDermott; S Mehta; H Ahn; P Greenland
Journal:  J Gen Intern Med       Date:  1997-04       Impact factor: 5.128

Review 4.  Intermittent claudication in older patients. Practical treatment guidelines.

Authors:  H Boccalon
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

Review 5.  Metabolic inertia in contracting skeletal muscle: a novel approach for pharmacological intervention in peripheral vascular disease.

Authors:  P L Greenhaff; S P Campbell-O'Sullivan; D Constantin-Teodosiu; S M Poucher; P A Roberts; J A Timmons
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

Review 6.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 7.  Optimal management of peripheral arterial disease for the non-specialist.

Authors:  M E O'Donnell; J A Reid; L L Lau; R J Hannon; B Lee
Journal:  Ulster Med J       Date:  2011-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.